A therapeutic strategy to target distinct sources of IgE and durably reverse allergy
Science Translational Medicine · 13.12.2023 · 15 (726)
DOI: 10.1126/scitranslmed.adf9561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 13.12.2023. Verfasst von Andre Limnander und 21 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Tarrytown, New York, 10591, USA. Hauptthemen laut MEDLINE: Immunoglobulin E, Anaphylaxis. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
Immunoglobulin E (IgE) is a key driver of type 1 hypersensitivity reactions and allergic disorders, which are globally increasing in number and severity. Although eliminating pathogenic IgE may be a powerful way to treat allergy, no therapeutic strategy reported to date can fully ablate IgE production. Interleukin-4 receptor α (IL-4Rα) signaling is required for IgE class switching, and IL-4Rα blockade gradually reduces, but does not eliminate, IgE. The persistence of IgE after IL-4Rα blockade may be due to long-lived IgE + plasma cells that maintain serological memory to allergens and thus may be susceptible to plasma cell–targeted therapeutics. We demonstrate that transient administration of a B cell maturation antigen x CD3 (BCMAxCD3) bispecific antibody markedly depletes IgE, as well as other immunoglobulins, by ablating long-lived plasma cells, although IgE and other immunoglobulins rapidly rebound after treatment. Concomitant IL-4Rα blockade specifically and durably prevents the reemergence of IgE by blocking IgE class switching while allowing the restoration of other immunoglobulins. Moreover, this combination treatment prevented anaphylaxis in mice. Together with additional cynomolgus monkey and human data, our studies demonstrate that allergic memory is primarily maintained by both non-IgE + memory B cells that require class switching and long-lived IgE + plasma cells. Our combination approach to durably eliminate pathogenic IgE has potential to benefit allergy in humans while preserving antibody-mediated immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Tarrytown, New York, 10591, USA.
ORCID-Profile: Andre Limnander, Navneet Kaur, Seblewongel Asrat, Carley Tasker, Li-Hong Ben, Paulina Pedraza, Pablo Abreu, Wen-Chi Chen, Benjamin J Daniel, Karen Rodriguez Lorenc, Olivier Harari, Neil Stahl, Matthew A Sleeman, Andrew J Murphy, Jamie M Orengo
Zitieren
APA
Limnander, A., Kaur, N., Asrat, S., Tasker, C., Boyapati, A., Ben, L. H., Janczy, J., Pedraza, P., Abreu, P., Chen, W. C., Godin, S., Daniel, B. J., Chin, H., DeVeaux, M., Rodriguez Lorenc, K., Sirulnik, A., Harari, O., Stahl, N., Sleeman, M. A., …, & Orengo, J. M. (2023). A therapeutic strategy to target distinct sources of IgE and durably reverse allergy. Science Translational Medicine, 15(726). https://doi.org/10.1126/scitranslmed.adf9561
Vancouver
Limnander A, Kaur N, Asrat S, Tasker C, Boyapati A, Ben LH, et al. A therapeutic strategy to target distinct sources of IgE and durably reverse allergy. Science Translational Medicine. 2023;15(726). doi:10.1126/scitranslmed.adf9561
BibTeX
@article{Limnander2023,
author = {Limnander, Andre and Kaur, Navneet and Asrat, Seblewongel and Tasker, Carley and Boyapati, Anita and Ben, Li-Hong and Janczy, John and Pedraza, Paulina and Abreu, Pablo and Chen, Wen-Chi and Godin, Stephen and Daniel, Benjamin J and Chin, Harvey and DeVeaux, Michelle and Rodriguez Lorenc, Karen and Sirulnik, Andres and Harari, Olivier and Stahl, Neil and Sleeman, Matthew A and Murphy, Andrew J and Yancopoulos, George D and Orengo, Jamie M},
title = {A therapeutic strategy to target distinct sources of IgE and durably reverse allergy},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {726},
doi = {10.1126/scitranslmed.adf9561}
}
EUVIMED